Novan Announces Receipt of Written Minutes from Type C Meeting with FDA Regarding Development of SB206
30 avr. 2020 16h05 HE
|
Novan, Inc.
Enrollment of first patient targeted for September 2020Top line results expected late in the second quarter of 2021 based on anticipated timeline MORRISVILLE, N.C., April 30, 2020 (GLOBE NEWSWIRE)...
Novan Announces Comprehensive Evaluation of Strategic and Financial Alternatives
20 avr. 2020 16h05 HE
|
Novan, Inc.
Engages H.C. Wainwright & Co. as strategic and financial advisorNITRICIL™ nitric oxide technology platform has enabled multiple early and late-stage pipeline opportunities in dermatology, women’s...
Novan Receives Verbal Guidance from FDA for SB206 and Announces Sato Program Advancement
03 avr. 2020 08h15 HE
|
Novan, Inc.
Per verbal guidance, FDA to consider one additional pivotal trialFDA-generated minutes expected on or before May 1, 2020Sato Pharmaceutical to begin start-up of Phase 1 trial in Japan MORRISVILLE,...
Novan Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market
26 mars 2020 16h05 HE
|
Novan, Inc.
MORRISVILLE, N.C., March 26, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company’s previously announced registered direct...
Novan Announces $8.0 Million Registered Direct Offering Priced At-the-Market
24 mars 2020 08h10 HE
|
Novan, Inc.
MORRISVILLE, N.C., March 24, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it has entered into definitive agreements with several institutional...
Novan Announces Data from B-SIMPLE Week 24 Safety Evaluation and COVID-19 Business Updates
23 mars 2020 08h15 HE
|
Novan, Inc.
Favorable SB206 Week 24 safety and scarring profilesType C teleconference with FDA for SB206 remains scheduled on April 1, 2020Novan intends to screen NVN1000 against a number of viruses, including...
Novan Announces Closing of $5.95 Million Public Offering, including Partial Exercise of the Underwriter’s Option to Purchase Additional Securities
03 mars 2020 16h05 HE
|
Novan, Inc.
MORRISVILLE, N.C., March 03, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company’s previously announced underwritten public...
Novan Announces Pricing of $5.5 Million Public Offering
27 févr. 2020 23h20 HE
|
Novan, Inc.
MORRISVILLE, N.C., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced the pricing of the Company's previously announced underwritten public...
Novan Announces Proposed Public Offering
27 févr. 2020 16h01 HE
|
Novan, Inc.
MORRISVILLE, N.C., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ: NOVN) today announced that it intends to offer and sell a combination of shares of its common...
Novan Receives Phase 2 NIH Federal Grant of Approximately $1.0 Million
20 févr. 2020 08h15 HE
|
Novan, Inc.
Provides funds to evaluate the mechanistic antiviral activity of WH602Novan to progress IND-enabling toxicology and pharmacology studies for WH602 Grant is additive to $223,000 Phase 1 NIH grant...